Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Breast Cancer
Intervention: Drug: pixantrone dimaleate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Procedure: Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
Sponsors: Memorial Sloan-Kettering Cancer Center; GE Healthcare
Recruiting - verified March 2010
Conditions: HER2 Positive; Metastatic Breast Cancer
Interventions: Drug: CT-P6; Drug: Herceptin; Drug: Paclitaxel
Sponsor: Celltrion
Not yet recruiting - verified March 2010
Condition: Female Breast Cancer
Intervention: Drug: Estradiol
Sponsor: University of Wisconsin, Madison
Recruiting - verified March 2010
Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone
Sponsor: City of Hope Medical Center
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Conditions: HER2 Positive; Metastatic Breast Cancer
Interventions: Drug: CT-P6; Drug: Herceptin; Drug: Paclitaxel
Sponsor: Celltrion
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: XL147; Drug: XL765; Drug: letrozole (Femara)
Sponsor: Exelixis
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET
Sponsor: University Medical Centre Groningen
Recruiting - verified February 2010
Conditions: Bone Cancer; Bone Metastases; Pain
Intervention: Device: ExAblate 2100
Sponsor: InSightec
Not yet recruiting - verified March 2010
Condition: Breast Cancer Mortality
Intervention: Other: Invitation for breast screening
Sponsors: University of Oxford; Department of Health, United Kingdom
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Other: 89Zr-bevacizumab PET imaging
Sponsor: University Medical Centre Groningen
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention:
Sponsors: University of Pittsburgh; National Center for Research Resources (NCRR)
Recruiting - verified March 2010
Condition: Neutropenia in Breast Cancer
Interventions: Drug: Filgrastim (Eurofarma); Drug: Filgrastim (Granulokine, Amgen)
Sponsor: Eurofarma Laboratorios Ltda
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: University of Arizona; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Breast Cancer; CYP2D6 Polymorphism
Intervention: Drug: Tamoxifen
Sponsor: Sydney West Area Health Service
Not yet recruiting - verified February 2010
Condition: Capsular Contractures
Intervention: Drug: Trental
Sponsor: Legacy Health System
Recruiting - verified March 2010
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin; Drug: PF-01367338; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Pfizer
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: ZD9393 (Zoladex); Drug: ZD9393 (Zoladex)
Sponsor: AstraZeneca
Not yet recruiting - verified February 2010
Condition: Adenocarcinoma of the Breast
Intervention:
Sponsor: Indiana University
Not yet recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Intervention: Drug: (will be assigned based on molecular profile and RPMA)
Sponsors: TGen Drug Development Services; SideOut Foundation
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention:
Sponsor: Park Nicollet Institute
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Procedure: Low-Level Laser Therapy
Sponsor: Northwestern University
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Radiation: APBI (Dose Escalation); Device: Contura MLB Breast Brachytherapy Catheter
Sponsor: SenoRx, Inc.
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: Paclitaxel,Gemcitabine,Sunitinib
Sponsors: National Cancer Center, Korea; Pfizer; CJ Cheiljedang Corporation
Recruiting - verified January 2009
Conditions: Breast Cancer; Bone Metastases
Intervention: Drug: Radium-223 chloride (Alpharadin)
Sponsor: Algeta ASA
Recruiting - verified March 2010
Conditions: Breast Cancer; Fatigue; Insomnia
Intervention: Procedure: Therapeutic Massage
Sponsors: Floyd Memorial Hospital and Health Services; Indiana University
Not yet recruiting - verified February 2010
Condition: Triple Negative Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab; Drug: Capecitabine
Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting - verified February 2010
Condition: Breast Cancer
Intervention:
Sponsor: Korean Breast Cancer Study Group
Recruiting - verified February 2010
Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastasis, Neoplasm
Interventions: Drug: docetaxel, cisplatin, esomeprazole; Drug: Docetaxel, cisplatin, esomeprazole; Drug: Docetaxel, cisplatin
Sponsors: Fudan University; Istituto Superiore di Sanita
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Daiichi Sankyo Inc.
Not yet recruiting - verified March 2010
Conditions: Severe Traumatic Brain Injury; Head Injury Severe; Traumatic Brain Injury; Brain Injuries
Interventions: Device: Parenchymal Intracranial pressure monitor; Other: Treatment based on clinical and imaging observations
Sponsor: University of Washington
Recruiting - verified February 2010
Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; GlaxoSmithKline
Recruiting - verified February 2010
Condition: Breast Density ≥ 50%
Intervention: Procedure: tomosynthesis
Sponsors: Alberta Health Services; Hologic, Inc.
Not yet recruiting - verified March 2010
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
Condition: Breast Cancer, Metastatic
Interventions: Drug: SAR240550 (BSI-201); Drug: Gemcitabine; Drug: Carboplatin
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Advanced Nonhematological Malignancies; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Healthy Volunteers
Interventions: Dietary Supplement: Single High Dose Cholecalciferol; Dietary Supplement: Daily Dose Cholecalciferol
Sponsor: Mayo Clinic
Recruiting - verified March 2010
Conditions: Breast Cancer; Breast Neoplasms
Interventions: Drug: XL147; Biological: trastuzumab; Drug: paclitaxel
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Aromasin; Drug: Aromasin
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: Duloxetine
Sponsors: University of Michigan Cancer Center; Eli Lilly and Company
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: capecitabine; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Magnetic Resonance Imaging
Interventions: Drug: Gadovist (Gadobutrol, BAY86-4875); Drug: Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Device: Support Device for Prone radiation therapy (Giro-Couch)
Sponsor: Azimuth Therapy Ltd.
Not yet recruiting - verified November 2009
Condition: Cancer
Interventions: Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes; Other: laboratory biomarker analysis
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Cancer; Neoplasms, Breast
Interventions: Drug: Lapatinib; Drug: Vinorelbine; Drug: Capecitabine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Stage IV Breast Cancer; Recurrent Breast Cancer
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Wyeth; Genentech
Recruiting - verified March 2010
Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: LY573636
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Urothelial Cancer; Bladder Cancer
Intervention: Drug: ABI-007 (Abraxane®)
Sponsors: University of Michigan Cancer Center; Abraxis BioScience Inc.
Recruiting - verified March 2010
Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified February 2010
Condition: Cancer
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsor: University Hospital Birmingham
Recruiting - verified September 2009
Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Avon Foundation
Recruiting - verified February 2010
Conditions: Breast Cancer; Prostate Cancer
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: BIIB021; Drug: BIIB021; Drug: exemestane (Aromasin)
Sponsor: Biogen Idec
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Radiation: WBRT; Drug: systemic therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Other: Side-effect questionnaires; Other: research blood samples
Sponsors: University of Chicago; Translational Breast Cancer Reserach Consortium; National Institutes of Health (NIH)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: tykerb
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: therapeutic dehydroepiandrosterone; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Behavioral: Online patient-provider communication service; Behavioral: WebChoice ITCA
Sponsors: Rikshospitalet HF; South-Eastern Norway Regional Health Authority
Recruiting - verified March 2010
Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Conditions: Advanced Solid Tumors Documented to be HER2+; Breast Cancer
Interventions: Drug: MK2206; Drug: Comparator: MK2206; Biological: Comparator: trastuzumab; Drug: Comparator: lapatinib
Sponsor: Merck
Recruiting - verified March 2010
Condition: Neoplastic Meningitis
Interventions: Drug: DepoCyt; Drug: Sorafenib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting - verified February 2010
Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel; Drug: pertuzumab; Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Recruiting - verified February 2010
Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: Herceptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: 5-fluorouracil; Drug: epirubicin; Drug: cyclophosphamide
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: evaluation of cancer risk factors
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2009
Condition: Breast Cancer
Interventions: Radiation: intracavitary balloon brachytherapy; Radiation: intraoperative radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: CAM nutritional therapy; Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Not yet recruiting - verified July 2009
Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Condition: HER2 Positive Breast Cancer
Interventions: Drug: docetaxel; Drug: trastuzumab-DM1 (T-DM1)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Tumors
Intervention: Drug: PKI-587
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Biological: Placebo of Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Drug: cyclophosphamide; Drug: sodium chloride
Sponsor: EMD Serono
Recruiting - verified March 2010
Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Procedure: Cone Beam CT
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin; Drug: Bevacizumab
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified January 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Invasive Breast Cancer
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Fondation du cancer du sein du Québec
Recruiting - verified May 2009
Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Intervention: Drug: doxorubicinhydrochloride, Lapatinib
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Pulmonary Fibrosis; Breast Cancer
Interventions: Drug: Tamoxifen; Radiation: Radiotherapy
Sponsors: Tata Memorial Hospital; Indian Council of Medical Research
Recruiting - verified May 2009
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified April 2009
Condition: Cancer
Interventions: Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Procedure: allogeneic bone marrow transplantation
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Cancer
Interventions: Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Solid Tumor
Interventions: Drug: ABT-263; Drug: paclitaxel; Drug: Carboplatin
Sponsors: Abbott; Genentech
Recruiting - verified January 2010
Condition: Breast Cancer
Intervention: Drug: RG1507
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Small Cell Lung Cancer
Intervention:
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Conditions: Vestibular Schwannoma; NF2; Neurofibromatosis 2; Acoustic Neuroma; Auditory Tumor
Intervention: Drug: lapatinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Children's Tumor Foundation; GlaxoSmithKline; New York University; Ohio State University; House Ear Institute
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: docetaxel; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: paclitaxel; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009
Conditions: Breast Neoplasms; Prostatic Neoplasms
Intervention: Biological: Anti-NGF AB
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: trastuzumab; Drug: lapatinib; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Baylor College of Medicine
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Device: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Sponsor: U-Systems, Inc.
Recruiting - verified February 2010
Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
Sponsors: BiPar Sciences; Breast Cancer Research Foundation
Recruiting - verified March 2010
Condition: Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: IMC-A12
Sponsors: ImClone LLC; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]; Drug: bevacizumab [Avastin]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 3 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 3 mg/kg, Capecitabine and Lapatinib
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: internet-based intervention; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: fatigue assessment and management; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Breast Cancer
Interventions: Drug: RG1507; Drug: letrozole
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Procedure: Echocardiograms; Procedure: Blood Test
Sponsors: M.D. Anderson Cancer Center; Massachusetts General Hospital
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: aldesleukin; Biological: allogeneic large multivalent immunogen breast cancer vaccine; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Neoplasms
Intervention: Other: Aromatase inhibitors
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Breast Neoplasms
Intervention: Other: Aromasin
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Abraxis BioScience Inc.; Genentech
Recruiting - verified February 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Standard chemotherapy or endocrine therapy
Sponsors: Hoffmann-La Roche; The Norwegian Radium Hospital
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Cancer
Interventions: Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes; Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Biological: therapeutic allogeneic lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunological diagnostic method; Other: laboratory biomarker analysis
Sponsors: Milton S. Hershey Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Advanced Breast Cancer
Interventions: Drug: Dasatinib + Fulvestrant; Drug: Fulvestrant
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Breast Cancer
Intervention: Drug: Tarceva
Sponsors: M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified March 2010
Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Neoplasm
Intervention: Drug: Pegylated Lyposomal Doxorubicin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Biological: IMCL-1121B
Sponsor: ImClone LLC
Recruiting - verified March 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: imatinib mesylate; Genetic: reverse transcriptase-polymerase chain reaction; Other: confocal microscopy; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: biopsy
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Device: Conture Multi-Lumen Balloon
Sponsors: Virginia Commonwealth University; SenoRx, Inc.
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2010
Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Drug: letrozole; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsor: Federation Nationale des Centres de Lutte Contre le Cancer
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: dexpantenol [Bepantol]; Drug: Corticosteroids; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: CBCT Scan; Procedure: OBI KV Imaging
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: ixabepilone; Drug: ixabepilone+cetuximab
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Cancer
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: rituximab; Drug: clofarabine; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Condition: Breast Cancer
Interventions: Drug: Anastrozole; Dietary Supplement: flaxseed; Drug: Placebo
Sponsors: Roswell Park Cancer Institute; National Center for Complementary and Alternative Medicine (NCCAM); AstraZeneca
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: Nab-paclitaxel; Drug: Trastuzumab (for HER2+); Drug: Bevacizumab
Sponsor: University of California, Irvine
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Trastuzumab; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: 5-fluoruracil; Drug: Granulocyte-colony stimulating growth factor; Drug: Trastuzumab
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2010
Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsor: Baylor College of Medicine
Recruiting - verified June 2009
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Conditions: Breast Neoplasm; Brain Neoplasm; Second Neoplasm
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Breast Cancer; Breast Surgery; Breast Reconstruction; Breast Reduction; Breast Augmentation
Interventions: Behavioral: questionnaires; Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; McMaster University; University College, London; Dartmouth-Hitchcock Medical Center
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Tumors
Intervention: Drug: Trabectedin; ET 743; Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar S.A.
Recruiting - verified February 2010
Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Suspicion of, or Known Breast Cancer
Intervention: Other: Radiology/MRI scan
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Condition: Sexual Dysfunction
Interventions: Behavioral: Focus Group; Behavioral: TENDRILS; Behavioral: Questionnaires; Behavioral: Sexual Counseling Sessions
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: 3'-Deoxy-3'-18F Fluorothymidine; Drug: 3'-Deoxy-3'-18F Fluorothymidine
Sponsor: Virginia Commonwealth University
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: FEC; Drug: Paclitaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Prostate Cancer; MRI
Intervention: Other: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Lapatinib; Drug: Trastuzumab; Drug: Endocrine
Sponsors: Baylor Breast Care Center; GlaxoSmithKline
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: fulvestrant
Sponsors: Accelerated Community Oncology Research Network; Hoffmann-La Roche; AstraZeneca
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Behavioral: Computer Program; Behavioral: Focus Group; Other: Written Materials
Sponsors: M.D. Anderson Cancer Center; National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH)
Recruiting - verified March 2010
Conditions: Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Carboplatin; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel + Carboplatin
Sponsors: AstraZeneca; KuDOS Pharmaceuticals Limited
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsor: Milton S. Hershey Medical Center
Recruiting - verified October 2007
Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: RAD001
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Gemcitabine; Drug: Sorafenib; Drug: Placebo; Drug: Capecitabine
Sponsors: Accelerated Community Oncology Research Network; Onyx Pharmaceuticals
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone & Trastuzumab; Drug: Docetaxel & Trastuzumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Procedure: Phlebotomy
Sponsors: M.D. Anderson Cancer Center; Myriad Pharmaceuticals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Taxane (docetaxel or paclitaxel)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tipifarnib; Procedure: axillary lymph node dissection; Procedure: conventional surgery
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsor: St. Bartholomew's Hospital
Recruiting - verified September 2007
Condition: Metastatic Breast Cancer
Intervention: Drug: ABI-007
Sponsor: Abraxis BioScience Inc.
Recruiting - verified January 2010
Conditions: Breast Cancer; Cervical Cancer; Prostate Cancer; Colorectal Cancer; Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Patient Navigator (PN)
Sponsors: M.D. Anderson Cancer Center; Centers for Medicare and Medicaid Services
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Second line chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Cancer
Interventions: Other: counseling intervention; Other: educational intervention; Procedure: psychosocial assessment and care
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: letrozole; Drug: methotrexate; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Epirubicin; Drug: Epirubicin; Drug: Docetaxel
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fluvastatin sodium; Other: clinical observation
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Breast Cancer
Interventions: Drug: tamoxifen; Drug: triptorelin; Drug: letrozole; Drug: zoledronic acid
Sponsors: National Cancer Institute, Naples; Second University of Naples
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: lithium carbonate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Prostate Cancer
Interventions: Other: internet-based intervention; Procedure: assessment of therapy complications
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: naltrexone hydrochloride; Procedure: computed tomography; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: Imatinib and Vinorelbine
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein; Other: flow cytometry; Other: immunohistochemistry staining method; Other: immunological diagnostic method; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lung Cancer; Breast Cancer
Intervention: Drug: Gefitinib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Conditions: Kallmann's Syndrome; Hypogonadotropic Hypogonadism; Healthy Volunteers
Interventions: Drug: Letrozole; Drug: NAL-GLU GnRH antagonist; Drug: GnRH
Sponsors: Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified February 2010
Conditions: Breast Cancer; Fatigue; Hypothyroidism
Interventions: Other: physiologic testing; Procedure: fatigue assessment and management; Procedure: management of therapy complications
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified November 2009
Condition: Cancer
Interventions: Other: laboratory biomarker analysis; Other: physiologic testing; Procedure: biopsy; Procedure: management of therapy complications
Sponsor: National Cancer Institute (NCI)
Recruiting - verified September 2006
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: moxifloxacin hydrochloride
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Breast Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: imatinib mesylate
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: CD4+CD25+ regulatory T cells; Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified September 2009
Condition: Breast Cancer
Intervention: Drug: Anastrozole
Sponsor: AstraZeneca
Recruiting - verified February 2010
Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2); Osteoporosis; Ovarian Cancer
Interventions: Drug: zoledronic acid; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole
Sponsors: American College of Surgeons; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: DCIS; Early Invasive Breast Cancer
Intervention: Drug: Anastrozole
Sponsor: University of California, Irvine
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: Biopsy; Procedure: Serum Collection; Procedure: Urine Collection; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Vinorelbine; Drug: Gemcitabine
Sponsors: Hoosier Oncology Group; Department of Defense; Indiana University School of Medicine; Walther Cancer Institute
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer (MBC)
Interventions: Drug: gemcitabine; Drug: docetaxel; Drug: paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Breast Neoplasms
Interventions: Drug: exemestane; Drug: anastrozole
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: caspofungin acetate
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
Conditions: Advanced Breast Cancer; Other Solid Tumors
Interventions: Drug: MK0752, Notch Inhibitor; Drug: MK0752, Notch Inhibitor - 450 mg; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off; Drug: MK0752, Notch Inhibitor - 1 day on, 6 off; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Sponsor: Merck
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Conditions: Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: recombinant interferon alfa; Drug: cyclophosphamide
Sponsor: Wiseman Research Initiatives, LLC
Recruiting - verified February 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Precancerous Condition
Intervention: Drug: exemestane
Sponsors: Lombardi Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Conditions: Breast Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: spectroscopy; Radiation: gadopentetate dimeglumine
Sponsors: American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified May 2007
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: ultrasound imaging; Radiation: gadopentetate dimeglumine
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Healthy
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified October 2009
Condition: Breast Cancer
Interventions: Procedure: conventional surgery; Radiation: radiation therapy
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified July 2009
Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
All Categories ... by Medical Condition » ... Cancers » ... Breast Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
